Previous Article | Next Article 
Journal of Clinical Microbiology, March 2001, p. 1200-1201, Vol. 39, No. 3
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.3.1200-1201.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Recurrent Self-Limited Fungemia Caused by Yarrowia
lipolytica in a Patient with Acute Myelogenous Leukemia
Chulhun Ludgerus
Chang,1,*
Tae Hee
Park,1
Eun Yup
Lee,1
Young Tak
Lim,2 and
Han Chul
Son1
Departments of Clinical Pathology1
and Pediatrics,2 College of Medicine,
Pusan National University, Pusan, Korea
Received 26 June 2000/Returned for modification 20 August
2000/Accepted 19 December 2000
 |
ABSTRACT |
Yarrowia lipolytica is a weakly pathogenic yeast that
is rarely isolated from the blood. We observed transient recurrent
catheter-related fungemia attributable to this organism in a leukemic
patient. The fungemia and accompanying fever subsided spontaneously.
The data suggest that it might be possible to withhold specific
treatment for Y. lipolytica fungemia even in an
immunocompromised patient.
 |
CASE REPORT |
A 15-year-old girl was found to have
acute myelogenous leukemia (AML, M1) in
December 1998. Induction chemotherapy with cytosine arabinoside,
idarubicin, and 6-thioguanine was initiated. After two courses of
induction chemotherapy, complete remission was obtained. In October
1999, during admission for the 7th cycle of maintenance chemotherapy,
two episodes of fever developed. A central venous catheter had been in
place at that time. Blood culture was performed with the VITAL
automatic system (BioMerieux, Marcy-l'Etoile, France), and anticancer
chemotherapy was stopped. Flucloxacillin and isepamicin were
administered empirically. Later, a yeast-like fungus was discovered and
identified as Yarrowia lipolytica by the Vitek YBC
(BioMerieux-Vitek, Hazelwood, Mo.) with bionumber 000402511 (99%) and
by the API 20C commercial system, version 2.2 (BioMerieux), with code
number 6002000 (92%). At the time of identification of the yeast, the
fever had subsided spontaneously. Anticancer chemotherapy was
continued, and the patient was discharged.
After an uneventful eighth cycle of chemotherapy, the patient was
readmitted to the hospital because of neutropenia (300 white blood
cells/µl) and mild fever. Bacteremia and an abscess of the left
forearm caused by Stenotrophomonas maltophilia were
diagnosed by cultures and treated by appropriate antibiotics and
incision and drainage of the abscess. Stenotrophomonas was
no longer isolated, and neutropenia and fever improved. A mild fever
developed 3 weeks after admission, and a blood culture was submitted.
The fever subsided without specific antibacterial or antifungal
therapy, and the patient was discharged. Y. lipolytica was
isolated from blood after the patient's discharge. The ninth cycle of
maintenance chemotherapy was completed uneventfully.
The patient was admitted in January 2000 complaining of high fever
(39.5°C). Blood was drawn for culture. Grasin (granulocyte colony-stimulating factor) was started because of severe neutropenia. Isepamicin and ampicillin were administered empirically. Her body temperature slowly decreased to baseline, and she was discharged. Again, Y. lipolytica was isolated. At the time of the next
admission, the central venous catheter was removed because of her
recurrent fungemia even though fever was not present, and Y. lipolytica was no longer isolated from her blood.
Discussion.
Y. lipolytica, also known as Candida
lipolytica, has been considered one of the emerging opportunistic
yeast pathogens (5). It has rarely been isolated from
patients with fungemia (3, 4, 6), and it was not included
in the long list in Hazen's careful 1995 review of emerging yeast
pathogens (2).
We observed a leukemic patient from whose blood Y. lipolytica was repeatedly isolated during febrile episodes. The
fever subsided without antifungal therapy. We report this case to
expand the understanding of Y. lipolytica fungemia. In the
present case, the patient had experienced three episodes of
self-limited fever because of Y. lipolytica fungemia that
were probably associated with her central venous catheter. These
findings are consistent with two previous reports (4, 6).
According to Wehrspann and Fullbrandt, it seems that the virulence of
Y. lipolytica is weak. Neither deep visceral infections nor
profound febrile reactions developed in the experimental cases. In the
present case, fever subsided without antifungal therapy, even though
the host was severely neutropenic. Another characteristic of Y. lipolytica fungemia is an association with vascular catheters. The
patient reported by Wehrspann and Fullbrandt (6) improved
after removal of the infected venous catheter. In a 54-year-old male
patient who had undergone cholecystectomy 1 month previously, fever
persisted for a week and intravenous catheter-associated
thrombophlebitis and accompanying fungemia were found. The fungemia
resolved upon removal of the catheter, with no antifungal therapy being
administered (4). Recently, a nosocomial outbreak of
Y. lipolytica fungemia in immunocompromised pediatric
patients was reported by Shin et al (3). In this outbreak,
all but one of the four cases were related to central venous catheters.
Upon treatment with amphotericin B, two acute myelogenous leukemic
patients were able to keep their Hickman catheters during the
subsequent chemotherapy cycles and until after allogenic bone marrow
transplantation. In the present case Y. lipolytica fungemia
was also absent after removal of the central venous line.
These two points raise confusion about dealing with the fungemic state
in a patient. It has generally been accepted that there
is at least a
40% mortality rate associated with candidemia (
1).
Therefore, most patients with vascular catheter-associated candidemia
should be treated with a course of amphotericin B, and, when possible,
the vascular catheter should be removed because of the risks of
subsequent deep visceral infection (
4). On the other hand,
none of the reported cases of
Y. lipolytica fungemia,
including
the present one, was complicated by a deep visceral
infection.
Furthermore, fever subsided spontaneously even in our
immunocompromised
patient. Given these observations, we think
that
Y. lipolytica fungemia does not cause severe or
long-sustained symptoms requiring
specific antifungal therapy. Thus, we
suggest that
Y. lipolytica is a weak pathogen and that
vascular catheter-associated fungemia
caused by this organism does not
need to be managed in the same
way as that caused by other
Candida spp. Specifically, antifungal
therapy or removal of
the vascular catheter is not necessary,
although the yeast may colonize
in the catheter and be seeded
into the bloodstream, resulting in
transient and recurrent fever.
However, most physicians have little
experience with
Y. lipolytica fungemia. So when a yeast-like
organism is found in a Gram stain
of the blood culture bottles or the
yeast is identified as
Y. lipolytica, the physician might
start antifungal therapy and remove
the catheter suspected of being the
source even if the fungemic
symptoms are no longer present. Actually,
it is believed that
the central venous catheter was unnecessarily
removed in the present
case. That is why the result should be urgently
reported to the
physician in charge, with communication of the weak
pathogenicity
of this organism and the association with
catheter-related fungemia,
when
Y. lipolytica is cultured
from the blood. Fortunately, it
is simple to identify a yeast isolate
as
Y. lipolytica within
a couple of days, because
identification kits such as the Vitek
YBC and API 20C are available in
many microbiology laboratories.
By these strategies, unnecessary
antifungal chemotherapy or removal
of central venous catheters can be
avoided. This also helps pediatric
patients, especially leukemic
patients receiving chemotherapy,
for whom catheter removal is
particularly undesirable, as it is
difficult to find new
vessels.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Clinical Pathology, College of Medicine, Pusan National University, #10 1-Ga Ami-Dong Seo-Gu, Pusan 602-739, Korea. Phone: 82-51-240-7417. Fax:
82-51-247-6560. E-mail: cchl{at}hyowon.cc.pusan.ac.kr.
 |
REFERENCES |
| 1.
|
Edwards, J. E., Jr.
1995.
Candida species, p. 2289-2306.
In
G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practices of infectious diseases, 4th ed. Churchill Livingstone, New York, N.Y.
|
| 2.
|
Hazen, K. C.
1995.
New and emerging yeast pathogens.
Clin. Microbiol. Rev.
8:462-478[Abstract].
|
| 3.
|
Shin, J. H.,
D. H. Shin,
T. J. Hwang,
M. Kim,
S. P. Suh, and D. W. Ryang.
2000.
Nosocomial cluster of Candida lipolytica fungemia in pediatric patients.
Eur. J. Clin. Microbiol. Infect. Dis.
19:344-349[CrossRef][Medline].
|
| 4.
|
Walsh, T. J.,
I. F. Salkin,
D. M. Dixon, and N. J. Hurd.
1989.
Clinical, microbiological, and experimental animal studies of Candida lipolytica.
J. Clin. Microbiol.
27:927-931[Abstract/Free Full Text].
|
| 5.
|
Warren, N. G., and K. C. Hazen.
1999.
Candida, Cryptococcus, and other yeasts of medical importance, p. 1184-1199.
In
P. R. Murray, E. J. Barron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
|
| 6.
|
Wehrspann, P., and U. Fullbrandt.
1985.
Report of a case of Yarrowia lipolytica (Wickerman et al.) van der Walt & von Arx isolated from a blood culture.
Mykosen
28:217-222[Medline].
|
Journal of Clinical Microbiology, March 2001, p. 1200-1201, Vol. 39, No. 3
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.3.1200-1201.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Levy, J. M., Levin, R. S., Clancy, J. T.
(2003). Lower-Extremity Wounds Inflicted by Rats. J. Am. Podiatr. Med. Assoc.
93: 58-61
[Full Text]
-
D'Antonio, D., Romano, F., Pontieri, E., Fioritoni, G., Caracciolo, C., Bianchini, S., Olioso, P., Staniscia, T., Sferra, R., Boccia, S., Vetuschi, A., Federico, G., Gaudio, E., Carruba, G.
(2002). Catheter-Related Candidemia Caused by Candida lipolytica in a Patient Receiving Allogeneic Bone Marrow Transplantation. J. Clin. Microbiol.
40: 1381-1386
[Abstract]
[Full Text]